A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
To explore the safety, tolerability and clinical effects of decitabine combined with R±DHAP
for patients with replase and refractory Diffuse Large B cell lymphoma.